Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celldex Therapeutics (CLDX) EPS (Basic) (2016 - 2025)

Celldex Therapeutics has reported EPS (Basic) over the past 16 years, most recently at -$1.23 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$1.23 for Q4 2025, down 73.24% from a year ago — trailing twelve months through Dec 2025 was -$3.9 (down 59.18% YoY), and the annual figure for FY2025 was -$3.9, down 59.18%.
  • EPS (Basic) for Q4 2025 was -$1.23 at Celldex Therapeutics, down from -$1.01 in the prior quarter.
  • Over the last five years, EPS (Basic) for CLDX hit a ceiling of -$0.34 in Q2 2021 and a floor of -$1.23 in Q4 2025.
  • Median EPS (Basic) over the past 5 years was -$0.63 (2023), compared with a mean of -$0.67.
  • Biggest five-year swings in EPS (Basic): skyrocketed 42.47% in 2021 and later plummeted 126.47% in 2022.
  • Celldex Therapeutics' EPS (Basic) stood at -$0.43 in 2021, then crashed by 32.56% to -$0.57 in 2022, then crashed by 47.37% to -$0.84 in 2023, then increased by 15.48% to -$0.71 in 2024, then tumbled by 73.24% to -$1.23 in 2025.
  • The last three reported values for EPS (Basic) were -$1.23 (Q4 2025), -$1.01 (Q3 2025), and -$0.85 (Q2 2025) per Business Quant data.